Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.62 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1313281 | 0.89 | PIK3CD (0.56) | PIK3CDDRD4DRD3L3MBTL1ABL1 | |
| SCHEMBL1313156 | 0.83 | PIK3CD (0.63) | PIK3CDDRD4DRD3L3MBTL1 | |
| SCHEMBL6983055 | 0.80 | PIK3CD (0.52) | PIK3CDATM | |
| SCHEMBL1313191 | 0.78 | PIK3CD (0.58) | PIK3CD | |
| SCHEMBL1312945 | 0.78 | PIK3CD (0.64) | PIK3CDDRD4DRD3L3MBTL1ATM | |
| SCHEMBL15471385 | 0.77 | PIK3CD (0.98) | PIK3CDDRD4DRD3L3MBTL1ATM | |
| SCHEMBL2438488 | 0.77 | PIK3CD (0.56) | PIK3CD | |
| SCHEMBL788676 | 0.77 | PIK3CD (0.58) | PIK3CD | |
| SCHEMBL6989437 | 0.77 | PIK3CD (0.58) | PIK3CDDRD4DRD3L3MBTL1 | |
| SCHEMBL4442988 | 0.77 | PIK3CD (0.63) | PIK3CDDRD4DRD3L3MBTL1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329910-B2 | Quinolines for the treatment of PI3K-δ mediated diseases | AMGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8183258-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20110281897-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110275811-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275811-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 15/4885DRD4 4339/4885DRD3 2523/4885 |
| US-20110281897-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 15/4885DRD4 4320/4885DRD3 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.